Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients
| dc.rights.license | open | en_US |
| dc.contributor.author | YAYA, I. | |
| dc.contributor.author | ROUX, P. | |
| dc.contributor.author | MARCELLIN, F. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTKOP, Linda | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ESTERLE, Laure | |
| dc.contributor.author | SPIRE, B. | |
| dc.contributor.author | DOMINGUEZ, S. | |
| dc.contributor.author | ELEGBE, B. A. | |
| dc.contributor.author | PIROTH, L. | |
| dc.contributor.author | SOGNI, P. | |
| dc.contributor.author | SALMON-CERON, D. | |
| dc.contributor.author | CARRIERI, M. P. | |
| dc.date.accessioned | 2021-01-07T10:54:51Z | |
| dc.date.available | 2021-01-07T10:54:51Z | |
| dc.date.issued | 2018-07-05 | |
| dc.identifier.issn | 1932-6203 (Electronic) 1932-6203 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/23733 | |
| dc.description.abstractEn | BACKGROUND: Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal toxicity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment with those of patients initiating DAA-based treatment. METHODS: ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units. Both clinical/biological and socio-behavioral data were collected during follow-up. We selected patients with socio-behavioral data available before HCV treatment initiation. RESULTS: A total of 580 patients were included in this analysis. Of these, 347 initiated PEG-IFN-based treatment, and 233 DAA-based treatment. There were significant differences regarding patient mean age (45 years+/-6 for the PEG-IFN group vs. 52 years+/-8 for the DAA group, p<0.001), unstable housing (21.4% vs. 11.2%, p = 0.0016), drug use (44.7% vs. 29.6%, p = 0.0003), regular or daily use of cannabis (24.3% vs. 15.6%, p = 0.0002), a history of drug injection (68.9% vs 39.0%, p<0.0001) and significant liver fibrosis (62.4% vs 72.3%, p = 0.0293). In multivariable analysis, patients initiating DAA-based treatment were older than their PEG-IFN-based treatment counterparts (aOR = 1.17; 95%CI [1.13; 1.22]). Patients receiving DAA treatment were less likely to report unstable housing (0.46 [0.24; 0.88]), cannabis use (regular or daily use:0.50 [0.28; 0.91]; non-regular use: 0.41 [0.22; 0.77]), and a history of drug injection (0.19 [0.12; 0.31]). CONCLUSION: It is possible that a majority of patients who had socio-economic problems and/or a history of drug injection and/or a non-advanced disease stage were already treated for HCV in the PEG-IFN era. Today, patients with unstable housing conditions are prescribed DAA less frequently than other populations. As HCV treatment is prevention, improving access to DAA remains a major clinical and public health strategy, in particular for individuals with high-risk behaviors. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | MORPH3Eus | |
| dc.subject.en | ANRS CO13 HEPAVIH | |
| dc.title.en | Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients | |
| dc.title.alternative | PLoS One | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1371/journal.pone.0199874 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29975764 | en_US |
| bordeaux.journal | PLoS ONE | en_US |
| bordeaux.page | e0199874 | en_US |
| bordeaux.volume | 13 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 7 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | MORPH3Eus | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20ONE&rft.date=2018-07-05&rft.volume=13&rft.issue=7&rft.spage=e0199874&rft.epage=e0199874&rft.eissn=1932-6203%20(Electronic)%201932-6203%20(Linking)&rft.issn=1932-6203%20(Electronic)%201932-6203%20(Linking)&rft.au=YAYA,%20I.&ROUX,%20P.&MARCELLIN,%20F.&WITTKOP,%20Linda&ESTERLE,%20Laure&rft.genre=article |
